Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 520 across all filing types
Latest filing 2025-09-10 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release issued by Medincell announcing the regulatory approval of their product UZEDY in South Korea. It provides details on the partnership, commercial performance, and future outlook. As it is a general corporate announcement regarding business operations and regulatory milestones that does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory filing.
2025-09-10 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release announcing the participation of Medincell's management in upcoming investor conferences (H.C. Wainwright and Morgan Stanley). It provides details on the dates, locations, and the nature of the participation (presentations and meetings). It does not contain the actual presentation slides or financial reports themselves, but rather serves as an announcement of the company's engagement with the investment community. Therefore, it falls under the category of a general regulatory announcement or corporate communication.
2025-09-05 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Medincell's management will be presenting at upcoming investor conferences (H.C. Wainwright and Morgan Stanley). It provides details on the dates, the presenters, and the nature of the events. It does not contain the actual presentation slides or a full financial report, but rather serves as an announcement of participation in investor relations activities. Therefore, it is classified as a Regulatory Filing (RNS) as it is a general corporate announcement that does not fit into more specific categories like 'Investor Presentation' (which would contain the slides) or 'Earnings Release'.
2025-09-05 English
Terms of availability of the preparatory documents for the GM
AGM Information Classification · 98% confidence The document is a press release titled 'Reminder of the Participation terms in the Combined General Meeting'. It provides instructions for shareholders on how to vote, attend, and submit questions for an upcoming Annual General Meeting (AGM). It does not contain the actual presentation materials or the results of the meeting, but rather serves as a procedural notice and invitation. According to the filing definitions, materials related to the logistics and solicitation of participation for an AGM fall under Proxy Solicitation & Information Statement (PSI).
2025-09-03 English
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 98% confidence The document is a press release from Medincell regarding the upcoming Annual General Meeting (AGM). It provides instructions on how to participate, vote, and access meeting materials. It is not the AGM presentation itself (AGM-R) nor a report of the results (DVA), but rather a notice/announcement regarding the meeting logistics and the availability of proxy materials. Therefore, it falls under the category of Proxy Solicitation & Information Statement (PSI) as it outlines the meeting agenda, voting procedures, and how shareholders can exercise their rights.
2025-09-03 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 95% confidence The document is a standard regulatory disclosure required under Article 223-16 of the AMF General Regulation in France. It provides the total number of shares and voting rights for MedinCell as of July 31, 2025. This type of filing is a routine regulatory update regarding capital structure and voting rights, which does not fit into specific categories like M&A, dividends, or earnings releases. Therefore, it is classified as a general regulatory filing.
2025-08-04 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.